Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAiLS: Phase 3 Study of Pridopidine in Amyotrophic Lateral Sclerosis
2025-524002-16-00Phase 3Authorised
- Sponsor
- Ferrer
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Pridopidine with Placebo (2 arms). Primary endpoints: ALSFRS-R change through Week 26 and ALSFRS-R change through Week 48. Planned start Apr 2026; status: authorised.
02
Drugs
pridopidine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2025-524002-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524002-16-00.